Nuclidium has begun a phase I clinical trial evaluating the use of copper-61 (Cu-61) in patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
The radiopharmaceutical is called Cu-61 NuriPro and is part of the company's NuriPro program, it said. The trial is being conducted at Hoag Memorial Hospital Presbyterian in Newport Beach, CA, and will evaluate the safety and effectiveness of Cu-61 NuriPro for imaging prostate cancer compared to an F-18 FDG-based PSMA-targeting radiotracer. Cu-61 NuriPro has a 3.3-hour half-life, compared with a one- to two-hour half-life of other molecular imaging agents, according to the firm.
